48-week results of a dual-therapy regimen of once-daily maraviroc (MVC) 150 mg in combination with ritonavir-boosted atazanavir (ATV/r) compared to emtricitabine/tenofovir (FTC/TDF) + ATV/r in treatment-naïve (TN) patients infected with CCR5-tropic HIV-1

TUAB0103

---

Time: 11:30
Speaker: Anthony Mills

You can download the mp3 file here

For more information on this presentation, including access to speaker presentations, please see the conference Programme-at-a-Glance page.